Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Aehr Test Systems (AEHR) Price & Performance

AbCellera Biologics IncTrade
Aehr Test SystemsTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Aehr Test Systems — how do they compare? AbCellera Biologics Inc trades at $9.03 (market cap $2.85B), while Aehr Test Systems trades at $118.58 (market cap $3.46B). The key difference: Aehr Test Systems is the larger of the two by market cap, and Aehr Test Systems is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.

ABCLAEHR
Market Cap
$2.85B$3.46B
Sector
HealthTechnology
52-Week High
$9.76$117.18
52-Week Low
$2.78$17.38
Enterprise Value
$2.45B$3.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Aehr Test Systems

AEHR Test Systems trades at $103.07, up 3.34% with strong technical momentum and bullish moving average signals. The company shows improving earnings trends with three consecutive quarterly beats, though profitability remains negative with a -14.25% net margin. Recent news highlights significant silicon photonics orders and a strategic pivot toward AI infrastructure, driving investor optimism despite insider selling activity.

Outlook remains growth-focused with FY27 revenue guidance of 160-200% expansion, though high valuation (P/S 65.13) and customer concentration pose risks. Analyst consensus leans neutral with 33% buy ratings, while technical indicators suggest near-term support at $97 with resistance at $107. The stock's AI-driven backlog expansion supports bullish sentiment despite current negative cash flow.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Aehr Test Systems

Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.

Read more on AEHR